688076 ST诺泰生物
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)15.40916.7437.9866.9388.317
总资产报酬率 ROA (%)7.5559.3775.3695.5546.552
投入资产回报率 ROIC (%)8.29710.3025.8796.0097.142

边际利润分析
销售毛利率 (%)68.46367.68560.97057.57355.756
营业利润率 (%)32.21227.58618.35119.17019.928
息税前利润/营业总收入 (%)34.62428.12317.87218.88519.925
净利润/营业总收入 (%)29.22424.60716.00818.85016.899

收益指标分析
经营活动净收益/利润总额(%)103.835112.187119.14384.003103.928
价值变动净收益/利润总额(%)0.105-0.3931.82614.6152.559
营业外收支净额/利润总额(%)-0.099-2.215-9.553-1.375-2.054

偿债能力分析
流动比率 (X)1.3381.1441.5361.9094.009
速动比率 (X)0.9280.8111.1481.3223.098
资产负债率 (%)53.15147.17838.28223.68514.958
带息债务/全部投入资本 (%)44.50038.05329.91915.1736.859
股东权益/带息债务 (%)114.507151.528224.103545.8821,326.533
股东权益/负债合计 (%)87.444111.048159.820319.750569.371
利息保障倍数 (X)14.17024.77815.938-752.24250.102

营运能力分析
应收账款周转天数 (天)107.53891.71594.334106.36068.995
存货周转天数 (天)399.465329.524312.642374.107275.370